The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 1 study. Full analysis set, LOCF. Includes patients with baseline DLQI total score >5.
bP < 0.001.
OTEZLA achieves significant and sustained improvement in QoL1
BID, twice daily; BL, baseline; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; DLQI, Dermatology Life Quality Index; LOCF, last observation carried forward; QoL, quality of life.
aLIBERATE study. Week 16 and week 104 responses were determined using the LOCF methodology. The analysis for week 16 includes all patients in the ITT group, while the week 104 analysis includes patients who entered the OTEZLA extension phase and were treated in the phase.
bP = 0.0032, OTEZLA vs placebo.
In biologic-naïve patients, OTEZLA achieves significant
and sustained improvement in QoL for up to 2 years2,3
*Response defined as a decrease of ≥5 points in DLQI total score in patients with baseline DLQI total score >5.
ITT, intent to treat; LIBERATE, Evaluation in a Placebo-Controlled Study of Oral Apremilast and Etanercept in Plaque Psoriasis.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
